Mesothelioma is a rare, aggressive cancer caused by asbestos exposure. It’s historically very hard to treat, but advancements are helping doctors understand why certain treatments are more effective for some patients than others.
Drugs called immune checkpoint inhibitors (ICIs) — like nivolumab (Opdivo®) and ipilimumab (Yervoy®) — have become important new options. ICIs essentially “release the brakes” on your immune system so it can better attack cancer cells.
For some mesothelioma patients, these drugs have been genuinely life-changing. But here’s the problem: While one patient may have their cancer shrink or stop growing, another may see little or no response.
A new study published in Lung Cancer may help explain why. Researchers found that mesothelioma patients with better outcomes after immunotherapy shared distinct patterns of tiny molecules called microRNAs, which help control how genes are used. These patterns were linked to changes that may make tumors easier to treat.
Learn more about what this means and why it matters for mesothelioma patients below.
About the MicroRNA Mesothelioma Immunotherapy Study
MicroRNAs are incredibly small molecules that play a large role in regulating how genes behave inside cells.
- They act like molecular volume controls, turning the activity of specific genes up or down.
- In cancer, they are frequently disrupted or lost, preventing them from properly regulating normal cell functions.
- With mesothelioma, many protective microRNAs go missing, allowing cancer-promoting processes to continue unchecked.
In other words, when these tiny molecules function properly, they help prevent cancer from growing. When they’re lost or disrupted — as they often are in mesothelioma — the cancer has a much easier time spreading and hiding from the immune system.
Understanding exactly which microRNAs are lost, and why, is a crucial piece of the puzzle in developing better mesothelioma treatments.
Download our Free Mesothelioma Immunotherapy Guide to better understand how immunotherapy works, who may be eligible, and what to expect.
How the MicroRNA Research Was Conducted
Previous research looked at microRNAs one at a time, which is like trying to understand a conversation by listening to only one person speak.
This study took a broader view, examining how microRNAs interact within larger systems called competing endogenous RNA networks (ceRNETs).
Think of these networks as ecosystems of molecules that compete with and influence each other. By studying the whole ecosystem, researchers got a much more accurate picture of what’s actually happening inside a tumor — and why some patients respond to immunotherapy while others don’t.
In the mesothelioma microRNA study, researchers:
- Used two large public databases of mesothelioma tumors to map patterns of microRNA activity
- Analyzed tumor samples from 44 patients treated with immune checkpoint inhibitors
- Divided patients into two groups based on whether they survived longer than 18 months after treatment
- Looked for differences in microRNA activity that could help explain why immunotherapy worked better for one group than the other
The fact that the researchers used real patient samples from clinical trials is significant. It means their findings weren’t based on a single group of patients, but were validated across multiple sources — making the results more reliable and more likely to hold up as research continues.
Results of the Mesothelioma Immunotherapy Success Study
The researchers found several important differences between patients who had better results with immunotherapy and those who didn’t. They also found the same patterns across multiple groups of patients, making the findings more reliable.
Here’s what they discovered:
- The same microRNA patterns appeared across both public datasets.
- Patients who survived longer than 18 months after immunotherapy had higher levels of certain microRNAs and lower levels of others.
- Many of those microRNAs were linked to changes that may make tumors less resistant to immunotherapy.
One finding stood out: the microRNAs didn’t appear to work alone. Instead, they acted together in larger RNA networks. Understanding how these networks influence immunotherapy response could help researchers improve treatment and identify patients who are most likely to benefit.
Immunotherapy isn’t right for everyone, which is why it’s important to work with a specialist. Our Free Doctor Match service can connect you with experienced mesothelioma specialists based on your diagnosis, treatment needs, and location.
What Does This Mean for Mesothelioma Patients?
The findings of this study have some genuinely practical implications — both in the near future and for the road ahead in mesothelioma care. The most immediate significance is the possibility of more accurately predicting who will respond to immunotherapy before treatment begins.
Right now, doctors have limited tools to make that call, which means some patients go through the side effects of immunotherapy without meaningful benefit. Analyzing a patient’s microRNA activity and ceRNA networks could help doctors make more informed, personalized treatment decisions.
That could mean:
- More patients receiving treatments that are actually likely to help them
- Fewer patients exposed to the side effects of treatments that are unlikely to work
- A clearer picture for doctors when weighing immunotherapy against other options
- Better conversations between patients and their care teams about what to expect
Often called precision medicine, this personalized approach has improved survival rates for several other types of cancer.
While microRNA research is still in its early stages, it suggests mesothelioma may be moving in the same direction. And for a cancer that has historically offered patients so few options, every step forward matters.
Talk With Someone Who Understands Mesothelioma
Immunotherapy can be an effective treatment for many patients, but it isn’t the right choice for everyone. That’s why it’s important to have a specialist review your diagnosis and recommend treatments that fit your specific situation.
If you’re looking for expert guidance, we’re ready to help. Our Patient Advocates can connect you with experienced mesothelioma specialists, answer your questions, and help you understand what treatments may be available.
Call (866) 608-8933 or fill out our contact form today. Our Doctor Match service is free, and we’re available 24/7 to help you find the care you deserve.
